Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Autotelic Bio","sponsor":"Oncotelic Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncotelic to Acquire Late-Stage Drug Candidate for Parkinson Disease, Erectile Dysfunction, and Female Sexual Dysfunction","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Autotelic Bio","sponsor":"Oncotelic Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncotelic Acquires Fast to Market Late-Stage Drug Candidate for Parkinson Disease, Erectile Dysfunction, and Female Sexual Dysfunction","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Autotelic Bio

    Menu

    Autotelic Bio

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Autotelic Bio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Oncotelic Acquires Fast to Market Late-Stage Drug Candidate for Parkinson Disease, Erectile Dysfunction, and Female Sexual Dysfunction

              Details:

              The acquisition of AL-101 brings in a product with a substantially large market potential for existing and unmet medical needs into the Company. AL-101 has shown a safety and efficacy profile and is phase 3 ready with 6 clinical trials completed and over 200 patients treated.

              Lead Product(s): Apomorphine Hydrochloride

              Therapeutic Area: Neurology Product Name: AL-101

              Highest Development Status: Undisclosed Product Type: Small molecule

              Partner/Sponsor/Collaborator: Oncotelic Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition October 04, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Autotelic Bio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Oncotelic to Acquire Late-Stage Drug Candidate for Parkinson Disease, Erectile Dysfunction, and Female Sexual Dysfunction

              Details:

              The acquisition of AL-101 (intranasal apomorphine), expands Oncotelic's product portfolio. AL-101 will also be developed as a new drug against Female Sexual Dysfunction ("FSD"), including Hypoactive Sexual Desire Disorder ("HSDD").

              Lead Product(s): Apomorphine Hydrochloride

              Therapeutic Area: Neurology Product Name: AL-101

              Highest Development Status: Undisclosed Product Type: Small molecule

              Partner/Sponsor/Collaborator: Oncotelic Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition September 01, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY